This is the authors' abstract. We don't add key points for this paper.
Background & aims: Patients who do not meet the criteria for Acute-on-Chronic Liver Failure (ACLF) at admission still face a high risk of disease progression and mortality. This study aimed to develop and validate a machine learning-derived clinical tool for the early identification of HBV-pre-ACLF. Methods: We analyzed 1,682 patients experiencing acute deterioration of HBV-related chronic liver disease but without ACLF. By random forest and SHAP analysis, we identified key predictors of ACLF onset within a 7-day window. We then validated the diagnostic thresholds in a test cohort of 260 patients. Results: Total bilirubin (TBIL) and INR were identified as the most critical predictors of ACLF progression. We established optimal diagnostic thresholds at TBIL ≥131.5 μmol/L and INR ≥1.35. Two sequential criteria were developed: pre-ACLF-O (meeting either threshold) for highly sensitive screening, and pre-ACLF-A (meeting both thresholds) for risk confirmation. In the derivation cohort, pre-ACLF-O achieved 98.3% sensitivity, while pre-ACLF-A predicted a 33.09% positive predictive value. These results were successfully validated in the test cohort, where pre-ACLF-O maintained 100% sensitivity and pre-ACLF-A demonstrated a 37.04% positive predictive value. Conclusions: This dual-indicator tool easily and effectively identifies HBV-pre-ACLF. Using these criteria sequentially provides a practical strategy for early risk stratification, allowing clinicians to initiate timely interventions for high-risk patients.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: